SCHEMBL10192173

SCHEMBL10192173

Cc1ccc(NC(=O)c2c(C)noc2C)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 1/20 0.74
GAA P10253 4/20 0.67
TP53 P04637 2/20 0.67
ALDH1A1 P00352 7/20 0.61
L3MBTL1 Q9Y468 2/20 0.61
RAB9A P51151 4/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
USP2 O75604 1/20 0.60
POLB P06746 1/20 0.60
ALOX15 P16050 2/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
NPC1 O15118 2/20 0.56
GLA P06280 1/20 0.56
HTT P42858 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
AGTR1 P30556 2/20 0.55
KDM4E B2RXH2 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31610836 0.85 GAA (0.76) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL23657488 0.85 KMT2A (0.67) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL4422171 0.85 GAA (0.72) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL7551575 0.84 GFER (0.66) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL6707794 0.84 GFER (0.65) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL7076714 0.80 GFER (0.60) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL12585052 0.80 MAPK1 (0.79) TP53ALDH1A1L3MBTL1SMN1; SMN2HTT
SCHEMBL7328008 0.80 GFER (0.60) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL6707261 0.80 GFER (0.60) GFERGAATP53ALDH1A1L3MBTL1
SCHEMBL14677761 0.80 GAA (0.68) GFERGAATP53ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2011-11-03 US disclosed
US-8013006-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-09-06 US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus PTC THERAPEUTICS, INC. 2008-04-24 US disclosed
WO-2007084413-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096928-A9 Indole compounds that modify translational control of Hepatitis C virus EIF2AK2, INMT, IDO1 GFER 2010/4885GAA 3537/4885TP53 1182/4885
US-20110268698-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, LIPC, HCCS GFER 2521/4885GAA 316/4885TP53 1579/4885
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS GFER 1552/4885GAA 163/4885TP53 3022/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS GFER 4263/4885GAA 667/4885TP53 1262/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS GFER 4263/4885GAA 667/4885TP53 1262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.